Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • GW4064: A Selective Non-Steroidal FXR Agonist for Metabol...

    2026-01-22

    GW4064: A Selective Non-Steroidal FXR Agonist for Metabolic Research

    Executive Summary: GW4064 is a synthetic, non-steroidal FXR agonist with high potency (EC50 ~15 nM in isolated receptor assays) and selectivity for the farnesoid X receptor. It modulates bile acid, triglyceride, and cholesterol metabolism in preclinical models, with documented efficacy in lowering serum triglycerides and VLDL secretion. GW4064 is characterized by poor water/ethanol solubility, UV instability, and a stilbene pharmacophore, which preclude therapeutic use but make it a valuable research tool. Its mechanism of action and role in the FXR/TLR4 pathway have been validated in recent cell and animal studies (Zhou et al., 2025). APExBIO supplies GW4064 (SKU B1527) for FXR-focused research applications.

    Biological Rationale

    The farnesoid X receptor (FXR; NR1H4) is a ligand-activated nuclear receptor central to bile acid homeostasis, lipid, and glucose metabolism in mammals. FXR regulates transcription of genes involved in bile acid synthesis (e.g., CYP7A1), transport, and enterohepatic circulation. Dysregulation of FXR signaling is implicated in metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), dyslipidemia, and fibrosis (Zhou et al., 2025). Agonists like GW4064 enable precise modulation of FXR activity, facilitating studies on metabolic, inflammatory, and fibrotic pathways. FXR activation also impacts the FXR/TLR4 pathway and ferroptosis, linking nuclear receptor signaling to liver fibrosis mechanisms.

    Mechanism of Action of GW4064

    GW4064 (3-[(E)-2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]ethenyl]benzoic acid) is a non-steroidal synthetic ligand. It binds and activates FXR with an EC50 of 15 nM in biochemical receptor assays and 90 nM in human FXR-transfected cells (APExBIO). Upon binding, GW4064 induces conformational changes in FXR, promoting coactivator recruitment and transcriptional activation of FXR target genes. This impacts bile acid transporters (e.g., BSEP), lipid metabolism genes, and represses pro-inflammatory pathways including TLR4. In hepatic stellate cell models, GW4064 reduces TLR4 expression, enhances ferroptosis features, and suppresses collagen deposition, a key step in fibrosis (Zhou et al., 2025).

    Evidence & Benchmarks

    • GW4064 activates FXR with an EC50 of 15 nM (receptor assay) and 90 nM (human FXR-transfected cells) (APExBIO).
    • In KK-Ay and ob/ob mice, GW4064 administration lowers serum triglycerides and VLDL secretion (internal article).
    • GW4064 treatment in LX-2 cells reduces TLR4 expression and collagen deposition, and increases ferroptosis markers, demonstrating antifibrotic activity (Zhou et al., 2025).
    • GW4064 is insoluble in water and ethanol, but soluble in DMSO at concentrations ≥24.7 mg/mL; recommended storage is -20°C (APExBIO).
    • GW4064 has been used to dissect the FXR/TLR4/ferroptosis axis in nickel oxide nanoparticle-induced liver fibrosis models (Zhou et al., 2025).

    This article updates and complements 'GW4064: A Selective Non-Steroidal FXR Agonist for Metabol...' by providing recent mechanistic evidence on GW4064's role in antifibrotic and ferroptotic pathways not previously detailed.

    Applications, Limits & Misconceptions

    GW4064 is primarily a research tool for interrogating FXR function in metabolic, liver, and fibrosis models. Its use is documented in:

    • Studies on cholesterol and triglyceride regulation via FXR activation.
    • Dissection of bile acid metabolism pathways and enterohepatic circulation.
    • Elucidation of FXR/TLR4 and ferroptosis signaling in liver fibrosis models (Zhou et al., 2025).
    • Evaluating FXR-dependent gene expression changes in animal and cell models.

    However, GW4064's utility is limited by several factors:

    • Poor solubility in aqueous and polar solvents (soluble only in DMSO).
    • UV light instability and short solution half-life.
    • Presence of a stilbene pharmacophore with potential toxicity; not suitable for clinical or in vivo therapeutic use.

    For a step-by-step troubleshooting guide and advanced experimental scenarios, see 'GW4064 (SKU B1527): Scenario-Driven Solutions for Robust ...', which addresses laboratory workflow optimization not covered here.

    Common Pitfalls or Misconceptions

    • GW4064 is not suitable for clinical therapy: Its toxic stilbene core and poor pharmacokinetics preclude clinical application (APExBIO).
    • Solubility constraints: It must be dissolved in DMSO, not water or ethanol; improper solvents can result in precipitation and loss of activity.
    • Photoinstability: Solutions degrade rapidly under UV exposure; store and handle under low-light conditions.
    • Short solution stability: Prepare fresh aliquots for each experiment; avoid long-term storage in solution.
    • Species-dependent FXR responses: Activity benchmarks may differ between human and rodent models; always verify receptor context.

    Workflow Integration & Parameters

    GW4064 (SKU B1527 from APExBIO) is supplied as a solid for research use. Key parameters:

    • Molecular weight: 542.85 g/mol; formula: C28H22Cl3NO4.
    • Solubility: Insoluble in water and ethanol; soluble in DMSO at ≥24.7 mg/mL.
    • Storage: -20°C; protect from light; short-term solutions recommended.
    • Concentration and dosing: Typical in vitro concentrations range 0.1–10 μM; always confirm cell line/animal protocol compatibility.
    • FXR specificity: GW4064 is highly selective for FXR over other nuclear receptors.

    For comprehensive applications in metabolic and fibrosis models, including troubleshooting and comparative analysis, see 'GW4064: Selective FXR Agonist Transforming Metabolic Diso...'. This resource details advanced techniques not explored in the present review.

    Conclusion & Outlook

    GW4064 remains a critical tool compound for dissecting FXR biology and its role in metabolic disease and fibrosis. Its nanomolar potency, selectivity, and reproducibility underpin its status as a research standard, despite solubility and stability constraints. Recent studies further validate the importance of FXR/TLR4/ferroptosis crosstalk in disease models (Zhou et al., 2025). As new FXR modulators evolve, GW4064 will continue to serve as a benchmark for mechanistic studies and protocol development. For ordering or technical specifications, refer to the GW4064 B1527 kit from APExBIO.